Evaluation of the efficacy, safety and and cost of home care versus conventional hospitalization care at 3-months in patients with worsening chronic heart failure.
Chronic heart failure (CHF) has an important socio-economic impact due to frequent hospital readmissions. Hypothesis: Home care treatment (HC) will improve quality of live and decrease cost. Methodology: Pilot, prospective, open, randomized controlled trial with 1-year follow-up for CHF patients admitted to 10 French hospital from March 2017 through February 2018, for acute decompensation of CHF. Patients will be randomly assigned to conventional hospital care or to the HC and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home. Follow-up will be conducted for both groups at discharge, 3 and 12 months after inclusion in the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
10
patients in Home care treatment (HC) group will be treated at home
Hôpital Henri Mondor
Créteil, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Time to rehospitalization
Time to rehospitalization for a new episode of acute heart failure within the first 3 months after the randomization.
Time frame: within the first 3 months after the randomization.
Occurrence of adverse events
Occurrence of adverse events evaluated at the end of the IV treatment which will be different for each patient.
Time frame: during hospitalization at the end of the IV treatment which will be different for each patient, average of 15 days
Quality of life (scales)
Quality of life (scales) at the end of the treatment and 3 months
Time frame: at the end of the treatment and 3 months
Nutritional status
Evaluation of the nutritional status based on MNA score at the beginning of the IV treatment and 3 months and dietary survey at the beginning and the end of the IV treatment.
Time frame: at the end of the treatment and 3 months
Mortality at the end of the treatment, 3 months and 1 year
Mortality at the end of the treatment, 3 months and 1 year
Time frame: at the end of the treatment, 3 months and 1 year
Cost-effectiveness
Cost-effectiveness at the end of the treatment, 3 months and 1 year
Time frame: at the end of the treatment, 3 months and 1 year
Time to first rehospitalization
Time to first rehospitalization for a new episode of acute heart failure within the first year after the randomization.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: within the first year after the randomization.